ROCKVILLE, Md., May 9, 2016 /PRNewswire/ -- Synthetic Biologics,
Inc. (NYSE MKT: SYN), a clinical stage company focused on
developing therapeutics to protect the gut microbiome, announced
Deb Mathews, PharmD, has joined the
Company in the new position of Vice President, Medical Affairs. Dr.
Mathews will be responsible for all medical affairs-related
activities, with a focus on supporting late-stage clinical
development for the Company's two lead GI microbiome-focused drug
candidates: SYN-010, designed to reduce methane production in the
gut to treat an underlying cause of irritable bowel syndrome with
constipation (IBS-C), and SYN-004, designed to prevent C.
difficile infection (CDI), antibiotic associated diarrhea (AAD)
and the emergence of antibiotic resistant organisms.
Dr. Mathews is a pharmaceutical and biotechnology executive with
over 20 years of clinical and medical affairs experience with
specialized therapeutic focus in both infectious disease and
oncology. Most recently she served as Executive Medical Science
Lead at Bayer Healthcare Pharmaceuticals, Inc. Prior to this, Dr.
Mathews served in various strategic medical affairs leadership
roles at Novartis, AstraZeneca, Tibotec Therapeutics and
GlaxoSmithKline, Inc.
"Deb brings a wealth of experience and enthusiasm to this newly
created strategic position," said Jeffrey
Riley, President and Chief Executive Officer of Synthetic
Biologics. "I am confident that her broad experience and strong
leadership will help maximize the clinical potential of our GI
microbiome-focused product candidates as we begin to implement
commercialization strategies."
Dr. Mathews received a Doctorate of Pharmacy degree from
Florida A&M University. Her
credentials also include HIV specialist certification from the
American Academy of HIV Medicine and membership with the American
Society of Microbiology.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical stage
company developing therapeutics to protect the gut microbiome while
targeting pathogen-specific diseases. The Company's lead candidates
in Phase 2 development are: (1) SYN-010 which is intended to reduce
the impact of methane producing organisms in the gut microbiome to
treat an underlying cause of irritable bowel syndrome with
constipation (IBS-C) and (2) SYN-004 which is designed to protect
the gut microbiome from the effects of certain commonly used
intravenous (IV) antibiotics for the prevention of C.
difficile infection and antibiotic-associated diarrhea (AAD).
In collaboration with Intrexon Corporation, the Company is also
developing preclinical stage monoclonal antibody therapies for the
prevention and treatment of pertussis and novel discovery stage
biotherapeutics for the treatment of phenylketonuria (PKU). For
more information, please visit Synthetic Biologics' website at
www.syntheticbiologics.com.
This release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. In
some cases forward-looking statements can be identified by
terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions, and include statements
regarding the expected contribution of Dr. Mathews and the
potential benefits of SYN-010 and SYN-004. These forward-looking
statements are based management's expectations and assumptions as
of the date of this press release and are subject to a number of
risks and uncertainties, many of which are difficult to predict
that could cause actual results to differ materially from current
expectations and assumptions from those set forth or implied
by any forward-looking statements. Important factors that
could cause actual results to differ materially from current
expectations include, among others, our ability to successfully
integrate the new management, a failure to receive the necessary
regulatory approvals for commercialization of Synthetic Biologics'
therapeutics, a failure of Synthetic Biologics' clinical trials,
and those conducted by investigators, for SYN-004 and SYN-010 to be
commenced or completed on time or to achieve desired results and
benefits, a failure of Synthetic Biologics' clinical trials to
continue enrollment as expected or receive anticipated funding, a
failure of Synthetic Biologics to successfully develop, market or
sell its products, Synthetic Biologics' inability to maintain its
material licensing agreements, or a failure by Synthetic Biologics
or its strategic partners to successfully commercialize products
and other factors described in Synthetic Biologics' most recent
Form 10-K, that was filed with the Securities and Exchange
Commission on March 10, 2016, and its
other filings with the SEC, including subsequent periodic reports
on Forms 10-Q and 8-K. The information in this release is provided
only as of the date of this release, and Synthetic Biologics
undertakes no obligation to update any forward-looking statements
contained in this release on account of new information, future
events, or otherwise, except as required by law.
Logo - http://photos.prnewswire.com/prnh/20160105/319502LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/synthetic-biologics-appoints-deb-mathews-pharmd-as-vice-president-medical-affairs-300264689.html
SOURCE Synthetic Biologics, Inc.